Skip to main content
NCBI home page
Infectious Diseases in Obstetrics and Gynecology logoLink to Infectious Diseases in Obstetrics and Gynecology
. 1995;2(5):223–227. doi: 10.1155/S1064744995000068

Teratogenic and Embryocidal Effects of Zidovudine (AZT) in Sprague-Dawley Rats

James T Christmas 1, Bertis B Little 1,✉, Kraig A Knoll 1, Roger E Bawdon 1, Larry C Gilstrap III 1
PMCID: PMC2364389  PMID: 18475397

Abstract

Objective: The purpose of the present investigation was to analyze the effets of zidovudine on the postimplantation embryo and fetus.

Methods: Pregnant Sprague-Dawley rats were given various doses (10 mg/kg, 30 mg/kg, 150 mg/kg) of zidovudine or saline by an endotracheal tube during the period of embryogenesis (days 6–8, 9–11, 6–11 postconception). The animals were sacrificed on days 18–19 of pregnancy, and their fetuses were removed by hysterotomy. Autopsies under low (15×) and high (40×) power light microscopy were performed on all fetuses.

Results: There was no statistically significant difference among the groups with respect to maternal weight gain. There were more pregnancy resorptions in the group receiving high-dose zidovudine (150 mg/kg/day) throughout embryogenesis than in the control group (P = 0.001, respectively). Four major structural anomalies were noted among the 689 fetuses examined, but zidovudine was not associated with an increased frequency of congenital anomalies in rats when it was administered in doses similar to, 3-, and 15-fold higher than the regimen recommended for adult humans. The drug, however, was embryocidal in the high-dose group (P = 0.002).

Conclusions: These findings are consistent with previous studies of preimplantation mouse embryos that demonstrated an embryocidal effect on preimplantation conceptuses. In summary, post-implantation embryonic zidovudine exposure was associated with significantly increased pregnancy losses (resorptions and intrauterine deaths).

Full Text

The Full Text of this article is available as a PDF (443.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bawdon R. E., Sobhi S., Dax J. The transfer of anti-human immunodeficiency virus nucleoside compounds by the term human placenta. Am J Obstet Gynecol. 1992 Dec;167(6):1570–1574. doi: 10.1016/0002-9378(92)91742-s. [DOI] [PubMed] [Google Scholar]
  2. Burke D. S., Brundage J. F., Herbold J. R., Berner W., Gardner L. I., Gunzenhauser J. D., Voskovitch J., Redfield R. R. Human immunodeficiency virus infections among civilian applicants for United States military service, October 1985 to March 1986. Demographic factors associated with seropositivity. N Engl J Med. 1987 Jul 16;317(3):131–136. doi: 10.1056/NEJM198707163170302. [DOI] [PubMed] [Google Scholar]
  3. Centers for Disease Control and Prevention (CDC) Zidovudine for the prevention of HIV transmission from mother to infant. MMWR Morb Mortal Wkly Rep. 1994 Apr 29;43(16):285–287. [PubMed] [Google Scholar]
  4. Chavanet P., Diquet B., Waldner A., Portier H. Perinatal pharmacokinetics of zidovudine. N Engl J Med. 1989 Nov 30;321(22):1548–1549. [PubMed] [Google Scholar]
  5. Fischl M. A., Richman D. D., Grieco M. H., Gottlieb M. S., Volberding P. A., Laskin O. L., Leedom J. M., Groopman J. E., Mildvan D., Schooley R. T. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23;317(4):185–191. doi: 10.1056/NEJM198707233170401. [DOI] [PubMed] [Google Scholar]
  6. Furman P. A., Fyfe J. A., St Clair M. H., Weinhold K., Rideout J. L., Freeman G. A., Lehrman S. N., Bolognesi D. P., Broder S., Mitsuya H. Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A. 1986 Nov;83(21):8333–8337. doi: 10.1073/pnas.83.21.8333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gogu S. R., Beckman B. S., Agrawal K. C. Amelioration of zidovudine-induced fetal toxicity in pregnant mice. Antimicrob Agents Chemother. 1992 Nov;36(11):2370–2374. doi: 10.1128/aac.36.11.2370. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Jackson G. G., Paul D. A., Falk L. A., Rubenis M., Despotes J. C., Mack D., Knigge M., Emeson E. E. Human immunodeficiency virus (HIV) antigenemia (p24) in the acquired immunodeficiency syndrome (AIDS) and the effect of treatment with zidovudine (AZT). Ann Intern Med. 1988 Feb;108(2):175–180. doi: 10.7326/0003-4819-108-2-175. [DOI] [PubMed] [Google Scholar]
  9. Klug S., Lewandowski C., Merker H. J., Stahlmann R., Wildi L., Neubert D. In vitro and in vivo studies on the prenatal toxicity of five virustatic nucleoside analogues in comparison to aciclovir. Arch Toxicol. 1991;65(4):283–291. doi: 10.1007/BF01968962. [DOI] [PubMed] [Google Scholar]
  10. Landesman S., Minkoff H., Holman S., McCalla S., Sijin O. Serosurvey of human immunodeficiency virus infection in parturients. Implications for human immunodeficiency virus testing programs of pregnant women. JAMA. 1987 Nov 20;258(19):2701–2703. [PubMed] [Google Scholar]
  11. Liebes L., Mendoza S., Wilson D., Dancis J. Transfer of zidovudine (AZT) by human placenta. J Infect Dis. 1990 Feb;161(2):203–207. doi: 10.1093/infdis/161.2.203. [DOI] [PubMed] [Google Scholar]
  12. Little B. B., Bawdon R. E., Christmas J. T., Sobhi S., Gilstrap L. C., 3rd Pharmacokinetics of azidothymidine during late pregnancy in Long-Evans rats. Am J Obstet Gynecol. 1989 Sep;161(3):732–734. doi: 10.1016/0002-9378(89)90391-8. [DOI] [PubMed] [Google Scholar]
  13. Mitsuya H., Weinhold K. J., Furman P. A., St Clair M. H., Lehrman S. N., Gallo R. C., Bolognesi D., Barry D. W., Broder S. 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A. 1985 Oct;82(20):7096–7100. doi: 10.1073/pnas.82.20.7096. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Richman D. D., Fischl M. A., Grieco M. H., Gottlieb M. S., Volberding P. A., Laskin O. L., Leedom J. M., Groopman J. E., Mildvan D., Hirsch M. S. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23;317(4):192–197. doi: 10.1056/NEJM198707233170402. [DOI] [PubMed] [Google Scholar]
  15. Schumacher H., Blake D. A., Gurian J. M., Gillette J. R. A comparison of the teratogenic activity of thalidomide in rabbits and rats. J Pharmacol Exp Ther. 1968 Mar;160(1):189–200. [PubMed] [Google Scholar]
  16. Sieh E., Coluzzi M. L., Cusella De Angelis M. G., Mezzogiorno A., Floridia M., Canipari R., Cossu G., Vella S. The effects of AZT and DDI on pre- and postimplantation mammalian embryos: an in vivo and in vitro study. AIDS Res Hum Retroviruses. 1992 May;8(5):639–649. doi: 10.1089/aid.1992.8.639. [DOI] [PubMed] [Google Scholar]
  17. Toltzis P., Mourton T., Magnuson T. Effect of zidovudine on preimplantation murine embryos. Antimicrob Agents Chemother. 1993 Aug;37(8):1610–1613. doi: 10.1128/aac.37.8.1610. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Yarchoan R., Berg G., Brouwers P., Fischl M. A., Spitzer A. R., Wichman A., Grafman J., Thomas R. V., Safai B., Brunetti A. Response of human-immunodeficiency-virus-associated neurological disease to 3'-azido-3'-deoxythymidine. Lancet. 1987 Jan 17;1(8525):132–135. doi: 10.1016/s0140-6736(87)91968-4. [DOI] [PubMed] [Google Scholar]

Articles from Infectious Diseases in Obstetrics and Gynecology are provided here courtesy of Wiley

RESOURCES